Eledon Pharmaceuticals, Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024. Unaudited consolidated results. Eledon is a clinical-stage biotechnology company developing tegoprubart, an anti-CD40L antibody, principally for kidney transplantation; it has no approved products and has not generated product revenue.
Key financial metrics
| Metric | Q1 2024 / March 31, 2024 | Comparable period / prior year-end |
|---|---|---|
| Revenue | No product revenue | No product revenue |
| Research and development expense | $7.410 million | $8.113 million in Q1 2023 |
| General and administrative expense | $3.459 million | $2.997 million in Q1 2023 |
| Total operating expenses | $10.869 million | $11.110 million in Q1 2023 |
| Net loss | $10.295 million; $0.34 per share | $10.772 million; $0.75 per share in Q1 2023 |
| Operating cash flow | -$8.741 million | -$9.924 million in Q1 2023 |
| Cash and cash equivalents | $5.655 million | $4.612 million at December 31, 2023 |
| Short-term investments | $37.207 million | $46.490 million at December 31, 2023 |
| Working capital | $43.7 million | As of March 31, 2024 |
| Total liabilities | $5.999 million | $5.647 million at December 31, 2023 |
| Accumulated deficit | $253.486 million | $243.191 million at December 31, 2023 |
Margins are not meaningful because the company reported no product revenue. The filing reports no outstanding debt or credit facility. Cash flow from investing activities was $9.783 million, mainly reflecting maturities of short-term investments partly offset by purchases; it is not operating cash generation.
Material changes versus Q1 2023
- Net loss narrowed by $0.477 million, while operating expenses declined by $0.241 million. R&D expense fell $0.703 million, mainly due to lower clinical-material production and CRO costs; G&A rose $0.462 million, primarily from higher stock-based compensation.
- Other income increased to $0.574 million from $0.338 million, largely reflecting interest income. Weighted-average shares rose to 29.99 million from 14.29 million; the lower loss per share therefore should be considered alongside substantial share-count growth.
- Operating cash use improved by $1.183 million year over year. The quarter included $1.694 million of noncash stock-based compensation.
Business outlook, liquidity, and risks
- After quarter-end, on May 6, 2024, Eledon agreed to a private placement that generated $50.0 million gross proceeds, approximately $47.6 million net. Management expects this financing plus March 31 cash and investments to fund operations through December 2025.
- Despite the stated runway, management reports substantial doubt about the company’s ability to continue as a going concern if additional capital cannot be raised. The runway estimate depends on assumptions, and the filing says resources could be exhausted sooner than expected.
- Potential additional funding under the 2023 private placement is contingent on specified clinical, share-price, and trading-volume conditions; warrant exercises are not assured. The May 2024 financing and outstanding warrants also create significant potential dilution.
- Clinical focus is on kidney transplantation. The Phase 1b study was ongoing and the 120-participant Phase 2 BESTOW trial began dosing in August 2023. The filing cites interim Phase 1b results reported in 2023, including generally favorable tolerability and mean eGFR above 70 mL/min/1.73m² at reported time points after day 90; these early results do not establish later-stage efficacy.
- Eledon says it cannot continue ALS clinical development without financing specifically for that program. The company discontinued IgA nephropathy development in 2023; an investigator-initiated islet-transplant study is not company-funded. Tegoprubart’s development remains subject to clinical, regulatory, manufacturing, and financing risks.
- Other material risks include dependence on third-party manufacturers and CROs, trial enrollment and safety uncertainties, competition, intellectual-property protection, market volatility, and potential cybersecurity or supply disruptions. No material legal proceedings or accrued contingent liabilities were reported.
Most important facts for investors to verify
- Whether the expected liquidity through December 2025 remains supportable as clinical spending and trial plans evolve, and whether further financing is needed.
- Progress, enrollment, safety, and outcome timing for BESTOW and the Phase 1b kidney-transplant trial.
- Whether any contingent 2023 placement tranches or warrants become available or are exercised, and the resulting dilution and share count.
- Whether dedicated financing is secured for ALS development and whether the company changes its program priorities.
- Whether early clinical observations are confirmed in larger or later-stage studies; the filing cautions that early results may not predict subsequent trials.